Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II Study of Tosedostat in Combination With Either Cytarabine or Decitabine in Newly Diagnosed AML or High-Risk MDS

Next Previous
X
Search
Trial Profile

A Phase II Study of Tosedostat in Combination With Either Cytarabine or Decitabine in Newly Diagnosed AML or High-Risk MDS

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 07 Apr 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Tosedostat (Primary) ; Cytarabine; Decitabine
  • Indications Acute myeloid leukaemia; Myelodysplastic syndromes
  • Focus Therapeutic Use

    • Most Recent Events

    • 10 Jun 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
    • 02 Jan 2014 Status changed from suspended to recruiting. The partial clinical hold on tosedostat has been lifted and studies underway may continue, according to a Cell Therapeutics media release.
    • 10 Dec 2013 Interim results presented at the 56th Annual Meeting and Exposition of the American Society of Hematology.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top